About This Tool

The Bavencio (avelumab) Dosing & Scheduling Tool calculator is designed for healthcare professionals to support the administration process of Bavencio. It provides calculated values for infusion parameters, generates a potential dosing schedule, and offers a quick-reference guide for managing adverse reactions based on the FDA-approved Prescribing Information.

Outputs

After entering the required patient and treatment information, the tool generates a comprehensive summary, which includes:

• Dosing Parameters: The standard 800 mg dose, the corresponding volume of Bavencio to withdraw (40 mL), the total infusion time (60 minutes), and the calculated infusion rate (250 mL/hr).
• Premedication Reminder: A prominent note reminding clinicians to consider premedication with an antihistamine and acetaminophen prior to the first four infusions.
• Treatment Schedule: A printable 12-cycle treatment schedule outlining infusion dates based on the provided start date and the standard every-2-weeks administration frequency.
• Adverse Reaction Guide: An interactive section to view dosage modifications and management recommendations for common immune-mediated adverse reactions.

How to Use

To use the calculator, follow these steps:

1. Patient Identifier: Optionally enter a non-identifiable reference (e.g., initials or a medical record number) for documentation.
2. Indication: Select the appropriate FDA-approved indication for Bavencio from the dropdown menu.
3. Patient Weight: Enter the patient's weight and select the unit (kg or lbs). This information is for documentation purposes only and does not alter the fixed 800 mg dose.
4. Treatment Start Date: Select the date of the first infusion or the current cycle's infusion date to generate an accurate forward-looking schedule.
5. Calculate: Click the "Calculate" button to generate the outputs.

Dosing Overview

The standard recommended dosage of Bavencio (avelumab) for all approved indications is a fixed dose, not based on patient weight.

Switching

This tool does not provide guidance on switching patients to or from Bavencio and other systemic therapies. All decisions regarding treatment sequencing or switching should be based on independent clinical judgment, current clinical guidelines, and the full Prescribing Information for all agents involved.

Missed Dose

The calculator generates a schedule based on a consistent 2-week interval. It does not provide guidance for managing a missed dose. Please refer to the full Prescribing Information or institutional protocols for instructions on how to proceed if a planned dose of Bavencio is missed.

Safety Alerts

Bavencio can cause immune-mediated adverse reactions, which may be severe or fatal. This tool includes a reference guide for management of specific reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Withhold or permanently discontinue Bavencio depending on the severity. Always consult the full Prescribing Information for complete warnings, precautions, and management guidelines.

Frequently Asked Questions (FAQ)

Does patient weight affect the dose of Bavencio?

No. The tool confirms that Bavencio is administered as a fixed dose of 800 mg, regardless of the patient's weight. The weight input is for documentation purposes only.

What is the recommended infusion rate for Bavencio?

The tool calculates an infusion rate of 250 mL/hr, based on administering a 250 mL infusion bag over 60 minutes.

For which indications is this dosing calculator applicable?

The calculator is designed for the approved indications listed in its dropdown menu: Metastatic Merkel Cell Carcinoma (MCC), certain types of Urothelial Carcinoma (UC), and Advanced Renal Cell Carcinoma (RCC) in combination with axitinib.

How many cycles does the generated treatment schedule display?

The tool provides a forward-looking schedule for the next 12 cycles of treatment, with each cycle occurring every 2 weeks.

What should I do for a Grade 3 infusion-related reaction?

According to the tool's adverse reaction guide, a Grade 3 or 4 infusion-related reaction requires permanent discontinuation of Bavencio.

Is premedication required for every dose?

The tool includes a reminder that premedication with an antihistamine and acetaminophen is recommended prior to the first 4 infusions of Bavencio.

What is the source of the information in this tool?

The data, including dosing and adverse reaction management, is sourced from the Bavencio (avelumab) Prescribing Information, with the last referenced version being August 2023.

Can I print the results?

Yes, the output is designed to be clear and organized, making it suitable for printing using your browser's print function for inclusion in patient records or as a reference.

References

This tool and its content are based on official product labeling and clinical resources. For complete and up-to-date information, always consult the primary sources.

1. BAVENCIO (avelumab) Prescribing Information. FDA. Revised: August 2023.
2. Bavencio HCP Official Website. EMD Serono, Inc. and Pfizer Inc.
3. Bavencio (avelumab) Summary of Product Characteristics (SmPC). European Medicines Agency.
4. Drugs@FDA Database. U.S. Food and Drug Administration.